Author:
Pan Hong,Shi Xiang,Jiang Yiguo,Wu Jiaqiang,Shen Li
Funder
2021 Suzhou High-tech Zone Health Talent Project.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Dranitsaris, G. et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann. Oncol. 28, 1260–1267 (2017).
2. Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
3. Zheng, R. S. et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 46, 221–231 (2024).
4. Rojas, C. & Slusher, B. S. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron). Cancer Treat. Rev. 41, 904–913 (2015).
5. Frame, D. G. Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J. Support Oncol. 8, 5–9 (2010).